-
2023-508841-42-00
3
2019-10-30
Different types of advanced cancer
-
2022-502354-14-00
5
2019-10-28
Completely resected Stage IIb/c melanoma
-
2024-510887-22-00
5
2019-09-30
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
-
2023-504624-25-00
4
2019-09-26
Advanced Non-Small Cell Lung Cancer
-
2023-504821-38-00
4
2019-09-19
Classical Hodgkin lymphoma in children and young adults
-
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
-
2023-507405-34-00
5
2019-08-07
First-line patients with advanced biliary tract cancers (BTC)
-
2024-511641-18-00
4
2019-08-01
Diffuse Large B-cell Lymphoma ABC
-
2022-502616-37-00
9
2019-07-30
Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
-
2022-502498-40-00
5
2019-07-26
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibr
-
2023-509605-77-00
1
2019-06-27
Advanced solid tumours
-
2024-514274-46-00
5
2019-06-21
Solid Tumors
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-512190-27-00
4
2019-05-13
Adults and children with full thickness skin defects
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer
-
2023-509834-20-00
4
2019-03-13
untreated FLT3-mutated Acute Myeloid Leukemia
-
2023-503812-34-00
4
2019-02-13
Locally Advanced or Metastatic Disease in Solid Tumors
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi
-
2024-511204-16-00
5
2019-01-23
Metastatic breast cancer
-
2024-516844-25-01
4
2019-01-03
Patients with ras-mutated metastatIc colorectal cancer
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C